Physician profile
William S Kasper
NPI 1851307987
$9,412.50
in general payments reported to CMS, 2019-2025
34 companies · $2,916 in 2025
The $2,916 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $290 · 2021: $666 · 2022: $984 · 2023: $1,187 · 2024: $2,291 · 2025: $2,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,394.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,192.49 | 2022-2025 | Simbrinza, Clareon, Tryptyr |
| Mallinckrodt Hospital Products INC. | $838.71 | 2024-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $756.86 | 2019-2025 | Cequa |
| Abbvie INC. | $679.59 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $614.36 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Aerie Pharmaceuticals, INC. | $602.34 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $531.05 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $358.48 | 2019-2025 | Idosetr |
| Allergan, INC. | $353.53 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $341.46 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Oyster Point Pharma, INC. | $317.03 | 2022-2025 | Tyrvaya |
| Genentech USA, INC. | $312.72 | 2023-2025 | Vabysmo |
| Horizon Therapeutics Plc | $301.99 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $293.35 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $196.68 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $184.14 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $154.32 | 2019-2022 | |
| Ocular Therapeutix, INC. | $133.84 | 2022 | |
| Rxsight INC | $132.96 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Penumbra, INC. | $129.56 | 2024 | Penumbra System |
| Astellas Pharma US INC | $127.09 | 2024-2025 | Izervay |
| Spark Therapeutics, INC. | $123.39 | 2019 | |
| Dompe US, INC. | $122.31 | 2024-2025 | Oxervate |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| Amgen INC. | $122.19 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $81.23 | 2024-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $71.29 | 2021 | |
| Biotissue Holdings INC. | $56.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $42.80 | 2021-2022 | |
| Thea Pharma INC. | $40.84 | 2024-2025 | Iyuzeh |
| Shire North American Group INC | $20.02 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.97 | 2024 | Rayone Spheric, Rayone Aspheric, Rayner Cataract Set 1 |
| Carl Zeiss Meditec USA, INC. | $18.42 | 2025 | Clarus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.